These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 8068879)
1. Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin. Churchill DN; Muirhead N; Goldstein M; Posen G; Fay W; Beecroft ML; Gorman J; Taylor DW J Am Soc Nephrol; 1994 Apr; 4(10):1809-13. PubMed ID: 8068879 [TBL] [Abstract][Full Text] [Related]
2. Does the use of erythropoietin in hemodialysis patients increase dialysis graft thrombosis rates? Standage BA; Schuman ES; Ackerman D; Gross GF; Ragsdale JW Am J Surg; 1993 May; 165(5):650-4. PubMed ID: 8488954 [TBL] [Abstract][Full Text] [Related]
3. Cost implications to Medicare of recombinant erythropoietin therapy for the anemia of end-stage renal disease. Powe NR; Griffiths RI; Bass EB J Am Soc Nephrol; 1993 Apr; 3(10):1660-71. PubMed ID: 8318682 [TBL] [Abstract][Full Text] [Related]
4. Vascular access thrombosis during recombinant human erythropoietin therapy. Tang IY; Vrahnos D; Valaitis D; Lau AH ASAIO J; 1992; 38(3):M528-31. PubMed ID: 1457917 [TBL] [Abstract][Full Text] [Related]
5. Relation between gender and vascular access complications in hemodialysis patients. Astor BC; Coresh J; Powe NR; Eustace JA; Klag MJ Am J Kidney Dis; 2000 Dec; 36(6):1126-34. PubMed ID: 11096036 [TBL] [Abstract][Full Text] [Related]
6. Effect of route of EPO administration on hemodialysis arteriovenous vascular access failure: a randomized controlled trial. Lee YK; Koo JR; Kim JK; Park II; Joo MH; Yoon JW; Noh JW; Vaziri ND Am J Kidney Dis; 2009 May; 53(5):815-22. PubMed ID: 19324483 [TBL] [Abstract][Full Text] [Related]
7. Long-term effects of erythropoietin therapy on fistula stenosis and plasma concentrations of PDGF and MCP-1 in hemodialysis patients. De Marchi S; Cecchin E; Falleti E; Giacomello R; Stel G; Sepiacci G; Bortolotti N; Zanello F; Gonano F; Bartoli E J Am Soc Nephrol; 1997 Jul; 8(7):1147-56. PubMed ID: 9219165 [TBL] [Abstract][Full Text] [Related]
8. Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients. Churchill DN; Muirhead N; Goldstein M; Posen G; Fay W; Beecroft ML; Gorman J; Taylor DW Clin Nephrol; 1995 Mar; 43(3):184-8. PubMed ID: 7774076 [TBL] [Abstract][Full Text] [Related]
9. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study. Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715 [TBL] [Abstract][Full Text] [Related]
10. Arteriovenous fistula thrombosis in patients on regular hemodialysis: a report of 171 patients. Roozbeh J; Serati AR; Malekhoseini SA Arch Iran Med; 2006 Jan; 9(1):26-32. PubMed ID: 16649374 [TBL] [Abstract][Full Text] [Related]
11. Recombinant human erythropoietin does not increase clotting in vascular accesses. Besarab A; Medina F; Musial E; Picarello N; Michael H ASAIO Trans; 1990; 36(3):M749-53. PubMed ID: 2252802 [TBL] [Abstract][Full Text] [Related]
12. Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor. Tobu M; Iqbal O; Fareed D; Chatha M; Hoppensteadt D; Bansal V; Fareed J Clin Appl Thromb Hemost; 2004 Jul; 10(3):225-32. PubMed ID: 15247979 [TBL] [Abstract][Full Text] [Related]
13. The role of hyperparathyroidism, erythropoietin therapy, and CMV infection in the failure of arteriovenous fistula in hemodialysis. Grandaliano G; Teutonico A; Allegretti A; Losappio R; Mancini A; Gesualdo L; Schena FP; Pertosa G Kidney Int; 2003 Aug; 64(2):715-9. PubMed ID: 12846770 [TBL] [Abstract][Full Text] [Related]
14. [Fistulae or catheter for elderly who start hemodialysis without permanent vascular access?]. García Cortés MJ; Viedma G; Sánchez Perales MC; Borrego FJ; Borrego J; Pérez del Barrio P; Gil Cunquero JM; Liébana A; Pérez Bañasco V Nefrologia; 2005; 25(3):307-14. PubMed ID: 16053012 [TBL] [Abstract][Full Text] [Related]
15. Hemodialysis access in the pediatric patient population. Lumsden AB; MacDonald MJ; Allen RC; Dodson TF Am J Surg; 1994 Aug; 168(2):197-201. PubMed ID: 8053526 [TBL] [Abstract][Full Text] [Related]
16. Effect of recombinant human erythropoietin on vascular access. Dy GR; Bloom EJ; Ijelu GK; Merritts GW; Kramer MS; Raja RM ASAIO Trans; 1991; 37(3):M274-5. PubMed ID: 1751146 [TBL] [Abstract][Full Text] [Related]
17. Effects of long-term treatment with recombinant human erythropoietin on physiologic inhibitors of coagulation. Jaar B; Denis A; Viron B; Verdy E; Chamma F; Siohan P; Mignon F Am J Nephrol; 1997; 17(5):399-405. PubMed ID: 9382155 [TBL] [Abstract][Full Text] [Related]
18. Hyperhomocysteinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients. Manns BJ; Burgess ED; Parsons HG; Schaefer JP; Hyndman ME; Scott-Douglas NW Kidney Int; 1999 Jan; 55(1):315-20. PubMed ID: 9893142 [TBL] [Abstract][Full Text] [Related]
19. Erythropoietin use in peritoneal dialysis patients. Zimmerman SW; Johnson CA Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):38-41. PubMed ID: 1928078 [TBL] [Abstract][Full Text] [Related]
20. The effect of erythropoietin treatment on arteriovenous haemodialysis fistula/graft: a prospective study with colour flow Doppler ultrasonography. Fischer-Colbrie W; Clyne N; Jogestrand T; Takolander R Eur J Vasc Surg; 1994 May; 8(3):346-50. PubMed ID: 8013687 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]